Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients wi... by Kivitz A, Ellis AM, Shende V, Lambert J, Tatla D

Get full text

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Treatment modes in rheumatoid arthritis: factors influencing patient preference by Taylor, P, Betteridge, N, Brown, T, Woolcott, J, Kivitz, A, Zerbini, C, Whalley, D, Olayinka-Amao, O, Chen, C, Dahl, P, Ponce de Leon, D, Gruben, D, Fallon, L

Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making by Taylor, PC, Betteridge, N, Brown, T, Woolcott, J, Kivitz, A, Zerbini, C, Whalley, D, Olayinka-Amao, O, Chen, C, Dahl, P, Ponce De Leon, D, Gruben, D, Fallon, L

Treatment modes in rheumatoid arthritis: Moving toward shared decision-making by Taylor, P, Betteridge, N, Brown, T, Woolcott, J, Kivitz, A, Zerbini, C, Whalley, D, Olayinka-Amao, O, Chen, C, Dahl, P, Ponce de Leon, D, Gruben, D, Fallon, L

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients by Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH